ChoA Pharmaceutical

At a glance

ChoA Pharmaceutical filed 22 disclosures in the last 12 months.

Revenue for 2025 was ₩59.3B, down 5.4% on 2024. It made an operating loss of ₩6.6B. Debt was 197% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩29.9B and operating loss of ₩1.1B.

The 2025 annual report lists 243 employees with an average tenure of 10.5 years and average pay of ₩62.4M, #856 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩233.3M each on average. It paid no cash dividend for 2025. 조원기 and related parties held 20.00% at year end.

From the 2025 annual report

Staff: 243 (180 men, 63 women), of whom 8 on fixed-term contracts. Total pay for the year: ₩15.2B. Directors and auditors: 6, paid ₩1.4B in total.

No cash dividend was paid for 2025.

Largest shareholder

조원기 holds 11.33%; with 2 related parties the group holds 20.00% of common shares at year end (from 19.57% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼도회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary